[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368262-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368262-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","humanized-mouse-models-of-kras-mutated-colorectal-and-pancreatic-cancers-with-hla-class-i-match-for-pre-clinical-evaluation-of-cancer-immunotherapies","Humanized mouse models of KRAS-mutated colorectal and pancreatic cancers with HLA-class-I match for pre-clinical evaluation of cancer immunotherapies","","Cancer immunotherapy seeks to improve outcomes for hard-to-treat KRAS-mutated colorectal cancer and pancreatic ductal adenocarcinoma, but many pre-clinical animal models poorly mirror patient tumor–immune interactions. Humanized mice offer promise for testing, yet commonly lack a human thymus needed for HLA-based education of T cells. Here, HLA-A2.1-expressing NRG-A2 transgenic humanized models enable HLA-class-I match across thymus, immune system, and tumors. CTL-mediated combination (immuno)therapy validates patient-relevant complexity and therapy-induced changes for pre-clinical immunotherapy development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/humanized-mouse-models-of-kras-mutated-colorectal-and-pancreatic-cancers-with-hla-class-i-match-for-pre-clinical-evaluation-of-cancer-immunotherapies/368262/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/humanized-mouse-models-of-kras-mutated-colorectal-and-pancreatic-cancers-with-hla-class-i-match-for-pre-clinical-evaluation-of-cancer-immunotherapies/368262.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are better pre-clinical animal models needed for KRAS-mutated CRC and PDAC immunotherapy?","Question",{"text":63,"@type":64},"Pre-clinical models often fail to accurately replicate human tumor–immune system interactions, including key aspects of tumor biology and the tumor microenvironment, limiting predictive value for immunotherapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitation do some humanized mouse models have regarding T cell education?",{"text":68,"@type":64},"They may lack a human thymus, which is necessary for HLA-based education and selection of human T cells, restricting the realism of T cell responses.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the study’s NRG-A2 model improve HLA-class-I matching?",{"text":72,"@type":64},"It uses transgenic NRG-A2 mice expressing HLA-A2.1 to enable HLA-class-I matching between mouse tissues (including thymus), the humanized immune system, and human tumors, supporting clinically relevant CTL activity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368262,1790260259,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ORIGINAL RESEARCH     \nHumanized mouse models of KRAS-mutated colorectal and pancreatic cancers with HLA-class-I match for pre-clinical evaluation of cancer immunotherapies  \nMaria E. Davola, Olga Cormier, Madeleine Lepard, Jamie McNicol, Susan Collins, Joanne A. Hammill, Christopher Silvestri, Jonathan L. Bramson, Amy Gillgrass, and Karen L. Mossman   \nDepartment of Medicine, Centre for Discovery in Cancer Research and McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada  \nABSTRACT  \nCancer immunotherapy promises to treat challenging cancers including KRAS-mutated colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) . However, pre-clinical animal models that better mimic patient tumor and immune system interactions are required. While humanized mice are promising vehicles for pre-clinical immunotherapy testing, currently used cancer models retain limitations, such as lack of a human thymus for human leukocyte antigen (HLA)-based education of human T cells. As cytotoxic T lymphocyte (CTL) activity underlies many immunotherapies, we developed more clinically relevant KRAS-mutated CRC and PDAC humanized cancer models using transgenic NRG-A2 mice expressing HLA-A2.1 to enable HLA-class-I match between mouse tissues (including the thymus), the humanized immune system and human tumors. Using these novel humanized cancer models and a CTL-mediated combination (immuno)therapy with clinical potential, we were able to recapitulate the complexity and therapy-induced changes reported in patient biopsies, demonstrating the use of these HLA-matched models for pre-clinical validation of novel immunotherapies.  \nARTICLE HISTORY  \nReceived 7 June 2024 Revised 17 December 2024 Accepted 24 February 2025  \nKEYWORDS  \nCancer immunotherapy; colorectal cancer; HLA class I match; HLA-A2 . 1;  \nhumanized cancer model; humanized mice; immune checkpoint inhibitors; KRAS; NRG-A2; pancreatic ductaladenocarcinoma  \nIntroduction  \nImmunotherapy has taken the main stage in cancer treatment given striking increases in survival and quality of life for patients. Worldwide, KRAS mutations represent ~45% and 90% of colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) cases, respectively, cancers poorly responsive to conventional therapies or KRAS-targeting. Although immune checkpoint inhibitor (ICI) efficacy in CRC and PDAC is limited, combination (immuno)therapies show promise in clinical studies.1,2 Immunotherapies use the patient’s immune system to induce anti-tumor responses. Modeling the tumor microenvironment (TME) is particularly important in understanding human tumor immunology and exploring novel immunotherapies. Existing pre-clinical mouse models have poor predictive value as they fail to recapitulate human immunology, tumor biology and TME dynamics. Given clinical trial costs and complexities,“development of pre-clinical models that translate to human immunity” was identified asthe \\#1 key challenge for cancer immunotherapy.3  \nHumanized mice (hu-mice), immunocompromised mice engrafted with human immune components, are being developed to recapitulate the human immune system in a mouse.4 Injection of human peripheral blood mononuclear cells (PBMCs) or lymphocytes (PBLs) is relatively straightforward, although while T cells survive engraftment, B cells are maintained at very low levels, and innate cell populations including myeloid and NK cells only survive for the first few days.  \nFurthermore, high levels of mature human T cells in PBMCderived hu-mice provoke acute graft-vs-host disease (GvHD), limiting experiment length.4 To avoid GvHD, knockout mice deficient for MHC class I and II have been used.5 Mice engrafted with human CD34+ hematopoietic stem cells (HSCs) from cord or adult-mobilized blood develop a more complete hematopoietic system with innate and adaptive immune cells, low numbers of red blood cells and platelets, and significantly delayed GvHD development.4 However, a remaining limitat","cbCaitsnrCTxC4yM","https://ap.wps.com/l/cbCaitsnrCTxC4yM","pdf",2128741,"English","# Abstract\n# Introduction\n## Limitations of existing pre-clinical models\n## Humanized mouse approaches and challenges\n## HLA-mediated T cell education strategies\n# Article metadata","[{\"question\":\"Why are better pre-clinical animal models needed for KRAS-mutated CRC and PDAC immunotherapy?\",\"answer\":\"Pre-clinical models often fail to accurately replicate human tumor–immune system interactions, including key aspects of tumor biology and the tumor microenvironment, limiting predictive value for immunotherapies.\"},{\"question\":\"What limitation do some humanized mouse models have regarding T cell education?\",\"answer\":\"They may lack a human thymus, which is necessary for HLA-based education and selection of human T cells, restricting the realism of T cell responses.\"},{\"question\":\"How does the study’s NRG-A2 model improve HLA-class-I matching?\",\"answer\":\"It uses transgenic NRG-A2 mice expressing HLA-A2.1 to enable HLA-class-I matching between mouse tissues (including thymus), the humanized immune system, and human tumors, supporting clinically relevant CTL activity.\"}]","Humanized mouse models of KRAS-mutated colorectal and pancreatic cancers with HLA-class-I match for pre-clinical evaluation of cancer immunotherapies | PDF",1790175923,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d4d1241726e50c53427a764c13125d4.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f0835e8040d0a0492ec56b0db8b18ca.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90f85e90f7848b58fbdbca6c33171be1.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1329c25c0ecf6fb2e8e87f550023fcad.webp",980,1306]